Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies. For more information, please visit KateTx's website at https://www.katetherapeutics.com/.
SOURCE Kate Therapeutics

https://www.katetherapeutics.com/

San Diego

Kate Therapeutics

Novartis is a global healthcare company based in Switzerland. It is focused on developing innovative medicines to improve and extend people's lives. The company operates in various therapeutic areas, including oncology, cardiology, and immunology. Novartis is known for its commitment to research and development.

https://www.novartis.com/

Switzerland

Novartis AG

Novartis has announced the acquisition of California-based biotech company Kate Therapeutics, as part of its strategic expansion into gene therapy and neuromuscular disorder treatments. This move aligns with Novartis' goal to deliver innovative treatments and deepen expertise in gene therapy for various neuromuscular conditions, aiming to tap into the projected $55 billion cell and gene therapy market opportunity by 2030.

Novartis acquires Kate Therapeutics to strengthen gene therapy portfolio

Novartis acquires Kate Therapeutics to strengthen gene therapy portfolio

Company Info

Related People